Welcome to our dedicated page for Praxis Precision Medicines SEC filings (Ticker: PRAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Praxis Precision Medicines, Inc. (NASDAQ: PRAX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Praxis is a clinical-stage biopharmaceutical company focused on central nervous system (CNS) disorders, and its filings offer detailed insight into the development and financing of its precision neuroscience portfolio.
Through Forms 8-K, Praxis reports material events such as topline clinical results, regulatory interactions and capital markets transactions. Recent 8-K filings describe positive Phase 3 Essential3 data for ulixacaltamide in essential tremor, EMBOLD study outcomes for relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies (DEEs), and RADIANT study data for vormatrigine in focal onset seizures and generalized epilepsy. Other 8-Ks outline pre-New Drug Application (NDA) meetings with the U.S. Food and Drug Administration (FDA), alignment on registrational pathways for elsunersen in early-onset SCN2A-DEE, and details of underwritten public offerings and at-the-market equity programs.
Investors can also use this page to monitor filings related to Praxis’ common stock listing on The Nasdaq Global Select Market under the symbol PRAX, shareholder meeting results, and executive compensation or governance matters disclosed in proxy-related documents. As Praxis advances ulixacaltamide, vormatrigine, relutrigine and elsunersen, its periodic and current reports are expected to discuss clinical progress, regulatory designations, risk factors and use of proceeds from financings.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand the significance of each PRAX filing. Real-time updates from EDGAR, combined with accessible explanations of complex disclosures, make this page a practical starting point for analyzing Praxis Precision Medicines’ regulatory and financial reporting history.
Praxis Precision Medicines, Inc. is conducting a primary offering of common stock and pre-funded warrants to raise cash for its neurology drug pipeline. The company will sell newly issued shares and, for certain investors, pre-funded warrants that are exercisable at $0.0001 per share, with ownership caps to limit any holder’s voting stake. As of December 31, 2025, Praxis reported preliminary cash, cash equivalents and marketable securities of approximately $925 million, giving it substantial funding alongside the new capital raise. The company expects to use proceeds, together with existing cash, to prepare for potential commercialization of late-stage product candidates, continue clinical development, advance earlier-stage programs and fund general corporate needs.
Praxis Precision Medicines reported multiple advances across its neurology pipeline. For ulixacaltamide, the company completed a successful pre-New Drug Application meeting with the U.S. Food and Drug Administration and gained alignment on NDA content, and now expects to finish its NDA submission in early 2026.
For relutrigine, Praxis announced positive registrational EMBOLD results in patients with SCN2A and SCN8A developmental and epileptic encephalopathies. Patients on relutrigine (n=51) achieved a 53% placebo-adjusted reduction in seizures over 16 weeks and a 66% increase in motor seizure-free days, with statistically significant improvements in clinician and caregiver global impression scores and no drug-related serious adverse events. Praxis plans to meet with the FDA and set NDA timing afterward.
For vormatrigine, full RADIANT data in focal onset seizures showed an 8-week 54% median seizure reduction, with FOS patients reaching 100% median weekly seizure reduction by week 8 and maintaining this through 16 weeks; more than 11% were seizure-free for the entire 8-week period and roughly one third for a consecutive 28-day period. Recruitment is complete for the POWER1 pivotal study in focal onset seizures, POWER2 is on track to finish in the second half of 2026, and the POWER3 monotherapy study is expected to begin in the first half of 2026.
Praxis Precision Medicines Chief Financial Officer reports stock purchase under employee plan
The Chief Financial Officer of Praxis Precision Medicines, Inc. (PRAX) filed a Form 4 disclosing the acquisition of company stock through the Praxis Precision Medicines, Inc. Employee Stock Purchase Plan. On 11/14/2025, the officer acquired 384 shares of common stock at a price of $31.62 per share in a transaction reported as an acquisition. Following this transaction, the officer beneficially owns 24,663 shares of Praxis common stock directly. The filing notes that the purchase was made under an employee stock purchase plan in transactions that were exempt under Rule 16b-3(d) and Rule 16b-3(c), which govern certain insider transactions for reporting and short-swing profit rules.
Praxis Precision Medicines (PRAX) insider filing: the company’s General Counsel and Secretary reported multiple stock option exercises and related share sales on 11/20/2025. The officer exercised options to acquire blocks of common stock at exercise prices of $44.4, $56.94, $83.85 and $133.65, then sold shares in several transactions, including 1,714 shares at a weighted average price of $190.863, 13,339 shares at $192.533, 977 shares at $193.233 and 9,100 shares at $194.3. After these transactions, the reporting person directly owned 20,831.667 shares of Praxis common stock, along with remaining stock options over additional shares that vest over time. The filing notes that the transactions were effected for estate planning purposes.
Praxis Precision Medicines (PRAX)11/20/2025, the officer exercised multiple stock options, acquiring Praxis common stock at exercise prices of $49.5, $83.85, $133.65, $43.37, $44.4, and $56.94 per share. The same day, the officer sold 11,455 shares at a weighted average price of $191.958 and 2,145 shares at a weighted average price of $192.711, in multiple transactions within narrow price ranges. After these transactions, the officer beneficially owned 10,441.656 shares of Praxis common stock directly. The filing notes that the transactions were effected for estate planning purposes, and several option grants referenced were already fully vested or continue to vest over time.
Praxis Precision Medicines (PRAX) filed its Q3 2025 report, showing higher R&D investment as late‑stage programs advance and a larger quarterly loss. Cash, cash equivalents and marketable securities were $389.2 million as of September 30, 2025. The company also completed an October 2025 public offering with $567.0 million in net proceeds, and states these resources will fund operations for at least one year from issuance and support program activities into 2028.
Q3 operating expenses reached $78.4 million (R&D $65.8 million; G&A $12.6 million), driving a net loss of $73.9 million versus $51.9 million a year ago. For the nine months, operating cash use was $172.7 million, offset by financing inflows including $89.3 million from at‑the‑market offerings. PRAX reported $14.8 million of other income year‑to‑date.
Shares outstanding were 21,165,933 as of September 30, 2025, and 25,007,171 as of October 31, 2025. Management highlights progress across ulixacaltamide (positive Phase 3 topline in October 2025), vormatrigine, relutrigine and elsunersen, while noting continued losses as development advances.
Praxis Precision Medicines (PRAX) reported that it announced its financial results for the quarter ended September 30, 2025. The company furnished a press release detailing these results as Exhibit 99.1.
The information under Item 2.02 and Exhibit 99.1 is being furnished, not filed, under the Exchange Act and is not subject to Section 18 liability, nor incorporated by reference unless specifically stated. PRAX’s common stock trades on The Nasdaq Global Select Market under the symbol PRAX.
Praxis Precision Medicines (PRAX) furnished an updated corporate presentation for investor meetings and disclosed a regulatory update for ulixacaltamide. The presentation is available on its website and is furnished as Exhibit 99.1 under Item 7.01.
Separately, the company reported that the FDA, after reviewing Essential3 topline results, granted a Type B meeting for ulixacaltamide to take place in the fourth quarter of 2025. Information provided under Item 7.01 is furnished and not deemed filed under the Exchange Act.
Praxis Precision Medicines announced an underwritten equity offering of 3,025,480 shares of common stock and pre-funded warrants to purchase up to 318,470 shares. The shares were priced at $157.00 each and the pre-funded warrants at $156.9999 per underlying share, reflecting a $0.0001 exercise price. The underwriters’ 30-day option to purchase up to 501,592 additional shares was exercised in full on October 17, 2025.
All securities are being sold by the company, with expected net proceeds of approximately $567.0 million after underwriting discounts and expenses, giving effect to the option exercise. Closing is expected on October 20, 2025, subject to customary conditions. The pre-funded warrants are immediately exercisable, permit cashless exercise, include 4.99% or 9.99% beneficial ownership limits (adjustable up to 19.99% on 61 days’ notice), and will not be listed on Nasdaq. The company plans to use proceeds to advance clinical programs, prepare for potential commercialization of late-stage assets, and for working capital, stating funding into 2028 when combined with existing cash.
Praxis Precision Medicines (PRAX) launched a primary offering of 3,025,480 shares of common stock at $157.00 per share and pre-funded warrants to purchase up to 318,470 shares at $156.9999 per underlying share. The company expects gross proceeds of $525,000,118.15, underwriting discounts of $31,500,009.00, and proceeds before expenses of $493,500,109.15. Underwriters have a 30-day option to buy up to 501,592 additional shares.
The company estimates net proceeds of approximately $493.0 million and plans to use them, together with existing cash, to fund R&D, prepare for potential commercialization of late-stage assets, advance earlier-stage programs, and for working capital and general purposes. Shares outstanding were 21,165,933 as of September 30, 2025, and are expected to be 24,191,413 immediately after the offering, excluding shares issuable upon exercise of the pre-funded warrants. The pre-funded warrants are exercisable at any time, carry a $0.0001 exercise price, and are subject to a 4.99% (or 9.99%) beneficial ownership limitation.